Background. The principal aim of this study was to determine the feasibility of a large-scale comparative study, between the UK, the Netherlands and Sweden, to investigate whether delays in the diagnostic pathway of cancer might explain differences in cancer survival between countries. Methods. Following a planning meeting to agree the format of a data collection instrument, data on delays in the cancer diagnostic pathway were abstracted from primary care-held medical records. Data were collected on 50 cases each (total of 150) from practices in each of Grampian, Northeast Scotland; Maastricht, the Netherlands and Skane, Sweden. Data were entered into SPSS 18.0 for analysis.
Introduction
Delay in cancer diagnosis and treatment has been researched internationally and several models describing the stages of delay have been produced. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] In general, these models identify three delays: those due to the patient, primary care and then secondary care.
The Eurocare 3 study reported considerable variation in medium-term cancer survival throughout Europe, with the UK and Scotland in particular, apparently performing relatively poorly. 15 For example, all-cause cancer survival appeared to differ markedly between Scotland, Sweden and the Netherlands despite similar proportions of common cancers in the three countries. 16 Overall, 5 year survival for men diagnosed with cancer in Scotland was 32.5% compared to 49.9% in Sweden and 41.6% in the Netherlands and for women 42.3%, 56.5% and 53.4%, respectively. 16 More recently, the first publication by the International Cancer Benchmarking Partnership that is based on data from national cancer registries has demonstrated consistently poorer survival from breast, lung, colorectal and ovarian cancer in the UK compared to Australia, Canada, Norway and Sweden, though comparable rates to Denmark. 17 The reasons for such international differences are not clear but some have suggested that they are due to factors such as longer diagnostic delays leading to later stage at diagnosis, lower uptake of screening and poorer access to primary and adjuvant treatment. 12 On the other hand, others have argued that the differences are spurious and relate instead to differences in the way national registries capture cancer data. 18 To date, a study directly comparing cancer diagnostic pathways between different European countries has not been undertaken. There are several important similarities and differences between health care in Sweden, the Netherlands and the UK. 19 In all three, almost all patients are registered with a GP who provides the first medical help about health concerns or symptomatic disease and acts as a gatekeeper to secondary care. In the three countries, the GP has a variety of diagnostic tests and investigation at their disposal; although the range and ability to access them directly differs. 19 In each country, GPs refer patients who they suspect might have cancer to secondary care. However, exactly how this is achieved varies. For example, in the UK, most are referred to a hospital outpatient department. In Sweden, referrals can be made directly to an 'Oncological Centre', whereas in the Netherlands, many GPs are able to access privately run diagnostic clinics where patients receive various investigations as day-case admissions. 19, 20 A study directly comparing cancer delays between the three countries could produce invaluable data. Firstly, it could confirm or refute the notion that cancer delays and stage at presentation differ in European countries. Secondly, it could begin to produce insights into how cancer services should be optimally configured for the shortest possible diagnostic delay. Such a study, however, is likely to be methodologically challenging. In this short paper, we report on a cross-sectional study, which investigated if information on the diagnostic pathway of cancer can be extracted from primary care records in Scotland, the Netherlands and Sweden and to conduct an exploratory analysis to determine whether there may be differences in diagnostic delay warranting further investigation.
Methods
Piloting of data collection methods Prior to starting this project, the UK researchers undertook a systematic search for current literature on diagnostic delay in cancer supported by a recent systematic review of factors influencing delay in all cancer sites. 21 Seven data sheets were devised to capture demographic details and dates of diagnostic milestones from Scottish primary care-held medical records. The colorectal module is included as an example (Appendix 1). This instrument was informed by methods developed and used successfully by the principal investigator to collect information on the diagnostic pathway of melanoma in Northeast Scotland [7] . The instrument was piloted in Northeast Scotland and amended as necessary. A Microsoft Access data entry form and database was constructed to handle the data.
Project meeting
In October 2009, a 2-day meeting was held in Aberdeen. At this meeting, the data collection instruments and Access database were discussed and subsequently modified in-line with the concerns of researchers from the three countries. Additionally, definitions of milestone dates in the cancer diagnostic pathway were agreed. 'It was agreed that the date of first presentation should be defined as the date on which the data collector judged the first primary care or other contact in the diagnostic sequence had occurred. It was recognized that in many cases, this date would be obvious; however, in some cases, individual clinicians would require judgement in assigning this date based on their detailed reading of the consultation notes around the appropriate period. Several potential scenarios were discussed in detail and agreement reached on how the date would be assigned in each case. A field was included, mode of presentation, so that the researcher could provide clarification of their decision if necessary. Date of GP referral was defined as the date on the corresponding referral letter. Letter dates were also used to assign the dates of hospital appointments, initial treatment and definitive treatment. A simple hierarchy was constructed as a source for the date of definitive diagnosis. Where possible this should be the date on pathology or investigation reports. If these were not available, it should be the date on a confirmatory hospital letter. Next in the hierarchy was the date the diagnosis appeared in a primary care consultation note and finally the date of entry to the primary care-held record problem list'.
Securing ethical approval
In each country, a copy of the research protocol was sent for review by the local research ethics committee for an opinion on whether full approval was necessary or the activity could be conducted as clinical audit. If full approval was required, then this was sought.
Identifying participants
In each country, 50 patients diagnosed with a range of cancers in the previous 3 years were identified (2007-10) . In Scotland, all practices are required to maintain a register of current cancer patients. The researcher (PM, one of the authors) scrutinized this register at his own practice and abstracted data on the first 50 patients diagnosed Family Practice-The International Journal for Research in Primary Care within the previous 3 years. In Swedish general practice, patients seldom get their cancer diagnosis registered as a diagnostic code in their file, so patients with cancer at a single Swedish practice (that of one of the authors, PR) were identified through the regional cancer registry, to which all malignant tumours (excluding non-melanoma skin cancer) are reported. From a list of all patients diagnosed at the practice within the previous 3 years and provided to the researcher (PR, one of the authors), the first 50 were selected. In the Netherlands, five GPs at five different general practices each identified the 10 patients most recently diagnosed with cancer at their practice (all within the previous 3 years) from their practice cancer register. The patients had a range of cancers including breast, colorectal, oesphagogastric, lung, melanoma, prostate, haematological, testicular, ovarian and bladder.
Main data collection
In each country, data were abstracted onto the data collection instrument. In each case, the non-translated English versions were used. Data were abstracted on demographic variables and cancer site, lifestyle factors and the dates of milestones in the diagnostic pathway. Scottish data were collected over the course of 2 weeks in November 2009 by a single GP (PM, one of the authors) at one practice. Electronic and paper records of each patient were reviewed and the paper diagnostic pathway data capture sheet was completed in each case. In the Netherlands, data were collected over 6 weeks in May and April 2010 by five GPs at five practices. Data were primarily available in and abstracted from electronic records, but paper records were examined to obtain additional data if necessary or in a few cases to verify information on the electronic data sheet. In Sweden, data collection took place over 10 weeks in July, August and September 2010 by a single GP (PR, one of the authors) at a single practice. Again, data were abstracted from both paper and electronic records.
Analysis
Data from the 150 cases were entered into Microsoft Access. Data were checked for consistency, cleaned and imported into SPSS 18.0 for statistical analysis. Summary statistics were produced for demographic data, cancer types, modes of referral from primary to secondary care, time intervals in the cancer diagnostic pathway (presentation to referral, referral to first contact in secondary care, first contact in secondary care to treatment and total overall delay) and missing data. Normally distributed continuous variables were compared across countries using one-way analysis of variance and skewed continuous variables were compared using the Kruskall-Wallis test. The chi-square test was used to assess the relationship of categorical variables across countries. Throughout all analyses, a P-value of <0.05 was used to denote statistical significance.
Results

Practical considerations
In Scotland and the Netherlands, the local ethics committees viewed the collection of anonymous data by GPs from their own patients as clinical audit, which did not require formal ethical approval or patient consent. In Scotland, the researchers were required to confirm this opinion with the local Caldecott Guardian who upheld this view. In Sweden, however, the participating GP was required to obtain written consent from each patient prior to collecting case-note data.
Patient characteristics
Patient characteristics and cancer sites are summarized in Table 1 . There was no significant difference in the sex distribution of the samples from the three countries. Swedish cases were, however, significantly older. There were some differences in the distribution of cancer types with a greater proportion of cases in Sweden and the Netherlands being lung cancer and a greater proportion of Scottish cases being colorectal cancer.
Availability and completeness of data
The dates of milestones in the cancer diagnostic pathway could be readily ascertained from primary-held care medical records in all three countries enabling the main delays to be calculated. Dates of treatment were often missing in the Swedish data and to a lesser extent in the Scottish data. This was usually where the patient had received no further treatment subsequent to the initial treatment (e.g. following a completely excised biopsy or had received palliative care only) or had not but where the date of this treatment decision was not available in the case records (Table 2) . We found that some variables were often missing: e.g. alcohol and tobacco use in Dutch and Swedish primary care-held medical records and stage at diagnosis in Scottish primary care-held medical records. Accessing secondary care Overall, there was no significant inter-country differences in the way in which primary care referred patients to secondary care (Table 3 ). In the Netherlands and Sweden, considerably more patients were admitted to a secondary care facility on the day of presentation rather than being referred to outpatients, but this difference was not statistically significant (22% versus 16% versus 2% for Sweden, the Netherlands and Scotland, respectively).
Comparison of diagnostic delays
There was no statistical inter-country differences in the median time delay between a patient presenting to primary care and being referred to secondary care (P = 0.313, Table 4 ). In contrast, median referral (P < 0.001), secondary care (P = 0.003) and overall delays (P = 0.003) were all significantly longer in Scotland than in Sweden or the Netherlands (Table 4) .
Discussion
Summary of main findings We found that information on delays in the cancer diagnostic pathway can be gathered from primary care-held case notes in Scotland, the Netherlands and Sweden. However, the recording of some variables, particularly demographic data, was variable. Ethical and regulatory requirements for this type of research differ between countries. Our preliminary findings suggest that patients experience similar delays in primary care but longer referral and secondary care delays in Scotland than the Netherlands or Sweden.
Strengths and limitations
This was a small pilot study conducted to assess the feasibility of collecting information about cancer diagnostic pathways in three different European countries. The study consumed few resources and demonstrated the feasibility of collecting most of the required data on delays in the cancer pathway in the three study countries and that it can be done relatively quickly and cheaply. It is important to note that in each country, it was worked out beforehand how cases would be selected for inclusion in the study. Thus, we can be quite clear that these are not convenience samples, drawn from only from cases in which the diagnostic pathway could be easily mapped.
A possible limitation is the fact that the samples are imbalanced for cancer site. There are more colorectal cancers in Scotland and more lung cancers from Sweden and the Netherlands. If there are systematic differences in the delays encountered in these cancers, then the countries in question could have been disadvantaged either way. On the other hand, at least in Scotland, delay appears to be similar for both cancer sites. 22 In terms of the sample size, the small numbers here creates difficulties in interpreting our data on delay. In the study, the difference in the Family Practice-The International Journal for Research in Primary Care proportions being admitted directly to hospital is not statistically significant; however, if these proportions were replicated in a larger study, it would be very important. This fact underpins the need for a larger study using the methods developed here. One of the objectives of this study was to quantify the extent to which lifestyle data were present or absent in primary care records since these could be important as confounders. In the event, much lifestyle information was not available suggesting that a larger study may need to incorporate additional methods, such as a patient questionnaire, to account for this. Such methods may offer the additional advantage of providing the opportunity to collect data on patient-induced delay, which clearly cannot be measured using the methods described here.
Comparison with other research To our knowledge, this study represents the first attempt to identify the practical issues facing researchers wishing to conduct a robust international comparison of cancer diagnostic delay based on primary health care records. Our finding that secondary care delays in Scotland are longer when directly compared to other European countries is striking and demands further investigation. Similarly, and although it did not reach statistical significance here, our finding that people with cancer are less likely to be immediately referred to secondary care in Scotland should be explored in a larger study. This is particularly so since the issue of poorer survival in the UK is contested. Some experts argue that apparent poorer survival in Scotland is spurious and can be explained by differences in data recording with weakness in the UK. 18 Others argue against supporting the quality of data recording and believing that differences are real. 23 Our data support this second view suggesting that there are differences in diagnostic pathways and the time taken before diagnosis, which may be important.
Meaning and implications
This project has demonstrated that a large-scale project comparing cancer diagnostic pathways between Sweden, the Netherlands and the UK based primarily on primary care records is feasible. Additional data will be required on stage at diagnosis and treatment, most of which could be collected from hospital case notes. There are cross-national differences in ethical and regulatory requirements for which planning will be needed. Our findings suggest that a larger scale project is warranted. Although our sample size was small, there were statistically significant differences in secondary care delay. These differences are despite similar health care expenditure in the three countries as a proportion of GDP and similar primary care-led health care systems. 18, 24 A larger study could provide cancer site-specific comparisons and more detailed comparisons may help to identify optimal diagnostic pathways.
In conclusion, a large-scale retrospective comparison of diagnostic pathways in different European countries is feasible, timely and important.
